%0 Journal Article
%T Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study
%A Thomas Babcock
%A Bryan Dirks
%A Ben Adeyi
%A Brian Scheckner
%J BMC Pharmacology and Toxicology
%D 2012
%I BioMed Central
%R 10.1186/2050-6511-13-18
%X Of 414 participants (62, placebo; 352, LDX) included in the overall study population, 41 were receiving AMPH therapy at screening (2, placebo; 39, LDX); mean AMPH dose was 35.0 and 34.1 mg/d for participants in placebo and all LDX groups, respectively. Of the 41 participants, 36 remained symptomatic (ADHD-RS-IV >18) at screening despite receiving AMPH. For the 36 participants in the placebo (n£¿=£¿2) and LDX (n£¿=£¿34) groups, respectively, at endpoint, mean change from screening ADHD-RS-IV total scores were -5.5 and -14.8 and from baseline scores were -13.5 and -17.8. For the overall study population, endpoint mean change from baseline ADHD-RS-IV total scores were -7.8 for placebo and -17.5 for LDX. In the prior AMPH subgroup, 2/2 (100.0%) in the placebo group and 22/39 (56.4%) participants in the LDX (all doses) group reported any TEAE. Events that occurred in ¡Ý5% for LDX were dry mouth (5/39; 12.8%), headache (5/39; 12.8%), fatigue (3/39; 7.7%), insomnia (3/39; 7.7%), decreased appetite (2/39; 5.1%), and nausea (2/39; 5.1%). None of these events occurred in the 2 placebo patients with prior AMPH use.In these post hoc analyses, adults with significant baseline ADHD symptoms despite adequate AMPH treatment dose showed similar improvements in ADHD symptoms with LDX treatment as the overall study population. Prospective studies are needed to confirm these findings. The safety profile of LDX in the overall study population was consistent with long-acting psychostimulant use.Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). Clinicaltrials.gov Identifier: NCT00334880Attention-deficit/hyperactivity disorder (ADHD) affects approximately 4.4% of adults in the United States [1]. Currently, psychostimulants, both amphetamines (AMPH) and methylphenidate (MPH), are considered first-line ADHD pharmacotherapy in adults [2-4]. Clinically nonresponsive patients treated with one psychostimulant will often obtain an improve
%K Lisdexamfetamine dimesylate
%K LDX
%K Amphetamines
%K Attention-deficit hyperactivity disorder
%K ADHD
%K Adult
%K Switching treatment
%U http://www.biomedcentral.com/2050-6511/13/18